From the Departments of Neurosciences (D.S.S., D.P.S., D.G., G.C.L., G.M.P., D.M.J., R.R., A.H.), Pathology (V.S.G., L.A.H., D.P.P., A.H.), and Family Medicine and Public Health (Y.Z., S.D.E.), University of California, San Diego; and VA San Diego Healthcare System (D.G., R.R., A.H.), CA.
Neurology. 2022 Feb 1;98(5):e506-e517. doi: 10.1212/WNL.0000000000013107. Epub 2021 Nov 22.
Patients with earlier age at onset of sporadic Alzheimer disease (AD) are more likely than those with later onset to present with atypical clinical and cognitive features. We sought to determine whether this age-related clinical and cognitive heterogeneity is mediated by different topographic distributions of tau-aggregate neurofibrillary tangles (NFTs) or by variable amounts of concomitant non-AD neuropathology.
The relative distribution of NFT density in hippocampus and midfrontal neocortex was calculated, and α-synuclein, TAR DNA binding protein 43 (TDP-43), and microvascular copathologies were staged, in patients with severe AD and age at onset of 51-60 (n = 40), 61-70 (n = 41), and >70 (n = 40) years. Regression, mediation, and mixed effects models examined relationships of pathologic findings with clinical features and longitudinal cognitive decline.
Patients with later age at onset of AD were less likely to present with nonmemory complaints (odds ratio [OR] 0.46 per decade, 95% confidence interval [CI] 0.22-0.88), psychiatric symptoms (β = -0.66, 95% CI -1.15 to -0.17), and functional impairment (β = -1.25, 95% CI -2.34 to -0.16). TDP-43 (OR 2.00, 95% CI 1.23-3.35) and microvascular copathology (OR 2.02, 95% CI 1.24-3.40) were more common in later onset AD, and α-synuclein copathology was not related to age at onset. NFT density in midfrontal cortex (β = -0.51, 95% CI -0.72 to -0.31) and midfrontal/hippocampal NFT ratio (β = -0.18, 95% CI -0.26 to -0.10) were lower in those with later age at onset. Executive function (β = 0.48, 95% CI 0.09-0.90) and visuospatial cognitive deficits (β = 0.97, 95% CI 0.46-1.46) were less impaired in patients with later age at onset. Mediation analyses showed that the effect of age at onset on severity of executive function deficits was mediated by midfrontal/hippocampal NFT ratio (β = 0.21, 95% CI 0.08-0.38) and not by concomitant non-AD pathologies. Midfrontal/hippocampal NFT ratio also mediated an association between earlier age at onset and faster decline on tests of global cognition, executive function, and visuospatial abilities.
Worse executive dysfunction and faster cognitive decline in people with sporadic AD with earlier rather than later age at onset is mediated by greater relative midfrontal neocortical to hippocampal NFT burden and not by concomitant non-AD neuropathology.
早发性散发性阿尔茨海默病(AD)患者比晚发性患者更有可能出现非典型的临床和认知特征。我们试图确定这种与年龄相关的临床和认知异质性是否是由tau 聚集神经原纤维缠结(NFT)的不同拓扑分布介导的,还是由伴随的非 AD 神经病理学的不同数量介导的。
计算了严重 AD 患者海马体和中前额皮质 NFT 密度的相对分布,并对发病年龄为 51-60 岁(n = 40)、61-70 岁(n = 41)和 >70 岁(n = 40)的患者进行了 α-突触核蛋白、TAR DNA 结合蛋白 43(TDP-43)和微血管共病的分期。回归、中介和混合效应模型研究了病理发现与临床特征和纵向认知衰退的关系。
AD 发病年龄较晚的患者出现非记忆症状(每十年的优势比[OR]为 0.46,95%置信区间[CI]为 0.22-0.88)、精神症状(β=-0.66,95%CI-1.15 至-0.17)和功能障碍(β=-1.25,95%CI-2.34 至-0.16)的可能性较低。TDP-43(OR 2.00,95%CI 1.23-3.35)和微血管共病(OR 2.02,95%CI 1.24-3.40)在较晚发病的 AD 中更为常见,而 α-突触核蛋白共病与发病年龄无关。中前额皮质 NFT 密度(β=-0.51,95%CI-0.72 至-0.31)和中前额/海马 NFT 比值(β=-0.18,95%CI-0.26 至-0.10)在发病年龄较晚的患者中较低。执行功能(β=0.48,95%CI 0.09-0.90)和视觉空间认知缺陷(β=0.97,95%CI 0.46-1.46)在发病年龄较晚的患者中受损程度较低。中介分析表明,发病年龄对执行功能缺陷严重程度的影响是由中前额/海马 NFT 比值介导的(β=0.21,95%CI 0.08-0.38),而不是由伴随的非 AD 病理学介导的。中前额/海马 NFT 比值也介导了发病年龄较早与全球认知、执行功能和视觉空间能力测试中更快认知衰退之间的关联。
早发性散发性 AD 患者的执行功能障碍和认知衰退较快,这与中前额皮质相对于海马体的 NFT 负担增加有关,而与伴随的非 AD 神经病理学无关。